Track 10x Genomics's intangible assets ($60M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), TXG shows a intangible assets of $60M. That compares with $15M in the prior-year period — up 294.4% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TXG's intangible assets is now $60M (was $15M) — a 294.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether 10x Genomics is outperforming or lagging.
Tracking TXG's intangible assets over time shows whether 10x Genomics is scaling, shrinking, or reshaping that part of the business. The current reading is $60M That compares with $15M in the prior-year period — up 294.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this intangible assets page, Stockcircle has 10x Genomics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $60M) with ownership activity and broader fundamentals.
10x Genomics's intangible assets is $60M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.